Only one patient, a 52-year-old woman with stage IA, ER-positive, PR-negative, HER2-negative and a Ki67 index of 20%, had an Oncotype Dx recurrence score (RS) of 15, indicating a low risk of cancer recurrence, and did not receive adjuvant chemotherapy. Here, ERBB2 is linked to cancer.